Nuova ricerca



Molecular modelling of dendrimers-polypeptide fibril interactions for neurodegenerative diseases therapies

Acronimo POLYDEN

Abstract Alzheimer's disease (AD) is one of the most common form of dementia. In 2006, there were 26.6 million sufferers worldwide, 10% of people over 65 years of age and 50% of those over 85 years of age have AD, which is predicted to affect more than 1% of population globally by 2050. It is recognized that AD is due to the deposition of fibrillar protein aggregates and gives rise to amyloid fibrils with shared structural features and properties. Currently used treatments offer a small symptomatic benefit; no treatments to delay or halt the progression of the disease are as yet available. The main idea of this project is to improve existing therapies, and to develop new therapeutic tools where none exist, by employing so-called dendrimers. Dendrimers are a new class of polymeric materials with a well-defined structure and they have shown to be the first compounds that not only have the ability to inhibit fibril formation but also disrupt aggregates. In this project, we plan to study the interactions of beta-amyloid peptides/fibrils with several types of dendrimers (e.g. amido-amine, PPI or carbosilane based ones ) applying computer atomistic and coarse-grained simulations.

Enti SUPSI coinvolti Laboratorio di biomateriali
Laboratorio per la matematica e fisica nell'ingegneria

Persone coinvolte Marek Maly

Responsabili Andrea Danani

Data di inizio progetto 1 giugno 2011

Data di chiusura progetto 31 dicembre 2015

 
st.wwwsupsi@supsi.ch